Creative Medical gets May 10, 2027 Nasdaq deadline

Q: When does CELZ need to regain Nasdaq bid-price compliance?

CELZ has a 180-day grace period through May 10, 2027. To regain compliance, its closing bid price must be $1.00 per share or more for a minimum of 10 consecutive business days.

Q: Does the Nasdaq notice immediately affect CELZ’s listing?

The notice has no immediate impact on CELZ’s listing. The company may qualify for an additional 180-day grace period if it meets Nasdaq Capital Market initial listing standards other than the minimum bid-price standard.

Available on EDGAR 11/13/2026 - 04:07 PM EST Accepted by SEC EDGAR 11/13/2026 - 04:05 PM EST

Filing Impact

(High)

Filing Sentiment

(Negative)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

8-K

Rhea-AI Filing Summary

Creative Medical Technology Holdings, Inc. (CELZ) received a Nasdaq notice that its closing bid price was below the $1.00-per-share minimum for 30 consecutive business days. The notice has no immediate impact on the company’s listing.

CELZ has a 180-day grace period through May 10, 2027, to regain compliance by closing at $1.00 per share or more for a minimum of 10 consecutive business days. It may qualify for an additional 180-day period if it meets Nasdaq Capital Market initial listing standards other than the minimum bid-price standard. The company said it will monitor its bid price and consider available options.

0 points · 0 major

How this balance works

Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.

It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.

Rhea-AI Sentiment measures something else, the tone of the wording.

How the balance works How Sentiment works

0 major · 1 point

How the balance works

Positive

None.

Negative

Moderate pointNasdaq bid-price deficiency: CELZ has until May 10, 2027 to regain compliance.

8-K Event Classification

2 items: 3.01, 9.01

2 items

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing Securities

The company received a delisting notice, failed to satisfy a continued-listing rule or standard, or transferred its listing.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, or exhibit attachments filed with this report.

Key Figures

Minimum bid price: $1.00 per share Below-minimum bid-price period: 30 consecutive business days Initial grace period: 180 days +2 more

5 metrics

Minimum bid price $1.00 per share Nasdaq said CELZ’s closing bid price was below this level for 30 consecutive business days.

Below-minimum bid-price period 30 consecutive business days Period cited in Nasdaq’s notice.

Initial grace period 180 days Through May 10, 2027, to regain compliance.

Compliance threshold 10 consecutive business days at $1.00 per share or more Closing bid-price condition to regain compliance.

Potential additional grace period 180 days CELZ may qualify if it meets Nasdaq Capital Market initial listing standards other than the minimum bid-price standard.

Key Terms

minimum bid price requirements, grace period, initial listing standards

3 terms

minimum bid price requirements regulatory

"Nasdaq minimum bid price requirements"

grace period regulatory

"a 180 day grace period"

A grace period is a short, pre-agreed span of time after a payment, filing, or other obligation is due during which a company or individual can meet the requirement without being penalized or declared in default. Think of it as a temporary breathing room that prevents immediate consequences for a missed deadline. Investors care because grace periods affect when cash flows are actually received, how soon penalties or defaults can hit, and the apparent credit risk and stability of an issuer.

initial listing standards regulatory

"Nasdaq’s initial listing standards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

When does CELZ need to regain Nasdaq bid-price compliance?

CELZ has a 180-day grace period through May 10, 2027. To regain compliance, its closing bid price must be $1.00 per share or more for a minimum of 10 consecutive business days.

Does the Nasdaq notice immediately affect CELZ’s listing?

The notice has no immediate impact on CELZ’s listing. The company may qualify for an additional 180-day grace period if it meets Nasdaq Capital Market initial listing standards other than the minimum bid-price standard.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding 8-K Material Events →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): November 10, 2026

Creative Medical Technology Holdings, Inc.

(Exact name of registrant as specified in its charter)

Nevada

000-53500

87-0622284

(State or other jurisdiction

of incorporation)

(Commission

File Number)

(I.R.S. Employer

Identification Number)

211 E Osborn Road, Phoenix, AZ 85012

(Address of principal executive offices)

(480) 399-2822

(Registrant’s telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.001 per share		CELZ		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

On November 10, 2026, Creative Medical Technology Holdings, Inc. (the “Company”) received a letter from The Nasdaq Stock Market stating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2) because the closing bid price of the Company’s common stock was below $1.00 per share for 30 consecutive business days. The notice has no immediate impact on the Company’s listing.

Pursuant to Nasdaq’s Listing Rules, the Company has a 180 day grace period, until May 10, 2027, during which the Company may regain compliance if the bid price of its common stock closes at $1.00 per share or more for a minimum of ten consecutive business days. The Company may be eligible for an additional 180-day grace period if the Company meets Nasdaq’s initial listing standards (other than with respect to minimum bid price) for The Nasdaq Capital Market.

The Company intends to actively monitor the bid price for its common stock between now and May 10, 2027, and will consider available options to regain compliance with the Nasdaq minimum bid price requirements.

Item 9.01 Financial Statements and Exhibits.

(d)

Exhibits.

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities and Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	Creative Medical Technology Holdings, Inc.

Date: November 13, 2026	By:	/s/ Timothy Warbington
		Timothy Warbington, Chief Executive Officer

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

5 documents